Astellas Reports Patient Death in Anemia Trial
Posted on: Tuesday, 8 May 2007, 15:00 CDT
Astellas Pharma has reported a death in its phase II trial of anemia drug YM311, which is being tested in patients with chronic kidney disease.
The patient died from fulminant hepatitis, also known as acute liver failure, according to the company. Astellas is jointly developing the compound with US biotech company FibroGen, which licensed the drug to Astellas for development and marketing in Europe and Japan. FibroGen is carrying out the trial in the US.
FibroGen has reported the case to the FDA and is discussing the cause and future plan, Astellas said. Astellas and FibroGen are analyzing the case.
Source: Datamonitor
Related Articles
- FibroGen Licenses Oral HIF-PH Inhibitors, Including FG-2216 and FG-4592, to Astellas for the Treatment of Anemia in Europe and Other Regions; FibroGen Positioned to Develop First Oral Anemia Therapy for North America
- Astellas Pharma Inc. Selects Additional Drug Targets for Diabetes and Obesity From Metabolex's Leading Gene Database
- Astellas, MerLion Enter Drug Discovery Agreement
- Astellas Pharma Inc. Extends Drug Discovery Collaboration With Metabolex Focused on New Therapeutics for Diabetes And Obesity
- Yamanouchi, Fujisawa Unite to Form Astellas Pharma US, Inc., North American Headquarters to Be in Chicago
- FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data From Phase 2A Study in Anemic Chronic Kidney Disease Patients
- FibroGen Announces FG-3019 Improves Kidney Function in a Late-Stage Disease Model of Diabetic Nephropathy
- FibroGen Investigational Small Molecule Anemia Therapy, FG-2216, Increased Endogenous EPO Production in Humans
- FibroGen Announces FG-3019 Found Safe and Well Tolerated in Patients With Idiopathic Pulmonary Fibrosis; Phase 1 Study Results of Investigational Anti-CTGF Therapy Reported at CHEST
Rating: 2.9 / 5 (9 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds